INT199551

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2006
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 2.63
Pain Relevance 0.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitosis (Rcc1) chromosome segregation (Rcc1) histone binding (Rcc1)
nucleus (Rcc1) cell cycle (Rcc1) DNA binding (Rcc1)
Rcc1 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 5 55.76 Quite High
Kinase C 1 50.96 Quite High
adenocard 1 16.60 Low Low
cva 12 5.00 Very Low Very Low Very Low
Central nervous system 6 5.00 Very Low Very Low Very Low
palliative 2 5.00 Very Low Very Low Very Low
imagery 2 5.00 Very Low Very Low Very Low
depression 1 5.00 Very Low Very Low Very Low
ischemia 1 5.00 Very Low Very Low Very Low
headache 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Renal Cancer 93 100.00 Very High Very High Very High
Renal Cell Carcinoma 50 100.00 Very High Very High Very High
Solid Tumor 8 99.50 Very High Very High Very High
Cancer 95 97.64 Very High Very High Very High
Small Cell Lung Cancer 2 95.28 Very High Very High Very High
Body Weight 1 89.24 High High
Breast Cancer 10 85.36 High High
Disease 44 80.96 Quite High
Malignant Neoplastic Disease 3 75.56 Quite High
Genetic Translocation 1 66.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These findings indicate that EZH2 may represent a novel therapeutic target for RCC treatment in that specific EZH2 inhibitors should repress tumor growth.
Regulation (target) of RCC associated with cancer and renal cancer
1) Confidence 0.01 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958940 Disease Relevance 1.03 Pain Relevance 0
It is unknown whether or not RCC is dependent on, or driven by, changes in receptor sensitivity to ligands.
Spec (whether) Regulation (dependent) of RCC associated with renal cell carcinoma
2) Confidence 0.01 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661649 Disease Relevance 0.70 Pain Relevance 0.03
An initial phase 1 study of single agent bevacizumab in 25 patients with metastatic treatment refractory solid tumors suggested its potential efficacy in RCC.14 The drug was well tolerated at doses of 0.1–10 mg/kg given every 28 days.
Regulation (efficacy) of RCC associated with renal cancer and solid tumor
3) Confidence 0.00 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2962304 Disease Relevance 0.90 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox